A recent publication from Bill Kaiserâ€™s and Ed Mocarskiâ€™s labs in Cell Host & Microbe touches on a concept that needs explaining: oncolytic viruses.
Viruses have been subverting the machinery of healthy cells for millions of years, and many viruses tend to infect particular tissues or cell types. So they areÂ a natural starting point for researchers to engineer oncolytic viruses, which preferentially infect and kill cancer cells.
Several oncolytic viruses have progressed to advanced clinical trials. Amgenâ€™s â€œT-Vecâ€, a modified herpes simplex virus, could be the first to be approved by the FDA this year based on its efficacy against metastatic melanoma.Â Read more